Hepatitis E in Germany--an under-reported infectious disease

Dtsch Arztebl Int. 2014 Sep 1;111(35-36):577-83. doi: 10.3238/arztebl.2014.0577.

Abstract

Background: At least 17% of the population in Germany has been infected with the hepatitis E virus (HEV); thus, HEV infections are more frequent than was previously assumed. However, fewer than 500 HEV infections were reported to the Robert Koch Institute in 2013.

Method: Review of pertinent literature retrieved by a selective search in PubMed.

Results: Persons living in Germany generally acquire hepatitis E infection within the country by consuming infected and undercooked pork; in rare cases, hepatitis E infections are imported from the tropics. HEV can be transmitted via blood products, blood transfusions, and organ transplantation. More than 99% of HEV infections are asymptomatic and self-limiting, but there are also severe cases with acute liver failure. Immunosuppressed persons can develop chronic HEV infection, potentially leading, within a few years, to liver cirrhosis with life-threatening sequelae. Moreover, HEV infection may be associated with extrahepatic manifestations such as Guillain-Barré syndrome. In two retrospectively evaluated case series, ribavirin was found to be active against HEV and can be used to treat either acute or chronic HEV infection.

Conclusion: Hepatitis E must be considered in the differential diagnosis of elevated hepatic enzyme levels and of systemic and neurological conditions of uncertain origin. The infection is usually self-limiting but can take a severe course in immunosuppressed persons. In such cases, ribavirin can be used as an antiviral treatment.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Aged
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Germany / epidemiology
  • Hepatitis E / diagnosis
  • Hepatitis E / drug therapy*
  • Hepatitis E / epidemiology*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Prevalence
  • Research Design / statistics & numerical data*
  • Ribavirin / therapeutic use*
  • Risk Factors
  • Young Adult

Substances

  • Antiviral Agents
  • Ribavirin